Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, a functionally selective muscarinic (M1) agonist, was found to be safe and well-tolerated when given orally to healthy male volunteers once-daily for four consecutive days. In two previous Phase I trials, NGX267, administered as single oral doses, was shown to be well-tolerated in healthy young adult males, as well as in healthy elderly males and females.

The purpose of the Phase I trial was to investigate the safety, tolerability and pharmacokinetics of multiple doses of NGX267 and to confirm data from previous studies in which NGX267 demonstrated evidence of muscarinic receptor stimulation as measured by increases in salivary flow. A total of 60 healthy males, between the ages of 18 and 55, were enrolled in the double-blind, placebo-controlled trial conducted at one center in Belgium. In a series of sequential dosing cohorts, subjects received a single oral dose of either 10, 20, 30 or 35 mg of NGX267 once-daily for four consecutive days. NGX267 was well tolerated at doses up to and including 30 mg, a dose range believed to be effective for treating memory and cognitive disturbances. TorreyPines plans to initiate a Phase II dose-ranging trial in CIAS during the first half of 2008.

A secondary objective was to obtain quantitative measures of salivary flow, prior to and at multiple time points post-dosing, as a peripheral biomarker for stimulation of the muscarinic receptor. In the study, increases in peak and total sal
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... 19, 2014 Follow us on ... the medical imaging market, are engineered to enhance the ... the past three decades have expanded the application roles ... iodine based agents used for over half a century ... imaging agents have witnessed sea changes, revolutionizing in the ...
(Date:9/19/2014)... 19, 2014 The ... Scandinavian style of eating, is making its ... Diet Doc’s medical weight loss ... eating good food which leads to improved ... teaching patients to understand how diet can ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
(Date:9/19/2014)... MD & Salt Lake City, UT (PRWEB) September 19, ... to launch the new Activz Greens Smoothie ... Products Expo East, September 18th-20th in Baltimore, MD. ... with 8 organic super foods combined in one convenient ... Natural Products Expo East, September 18th-20th in Baltimore, MD. ...
(Date:9/19/2014)... Prussia, PA (PRWEB) September 19, 2014 ... Business Process Outsourcing solutions for Health Plans in ... Medicaid markets, will sponsor a Networking Breakfast Session ... the Health Industry Advisory Practice at Pricewaterhouse Coopers, ... at the AHIP’s 2014 National Conference on Medicare ...
Breaking Medicine News(10 mins):Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 2Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 3
... CORONA, Calif., Feb. 19 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today reported financial results for its fourth quarter ... Fourth Quarter 2008 Results , ... increased $17.9 million or 3,percent from the fourth quarter ...
... to Vote Gold Card and Reject Dissidents, Director Slate ... (Nasdaq: LCAV ) today announced that it ... it urges support for Company management and its Board ... letter follows: To My Fellow Stockholders:Your LCA-Vision executive Team ...
... Full-Year 2009 OutlookVIRGINIA BEACH, Va., Feb. 19, 2009 AMERIGROUP ... net income for the fourth quarter of 2008 increased 20.0% ... income of $31.1 million, or $0.57 per diluted share, for ... December 31, 2008, the Company,s net loss was $50.7 million, ...
... foundation, announces its series of dental related health care reports under ... ... Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation ... related health care reports under the title of ,Elements of Disease., ...
... greenhouse gas emissions, Oregon will face some $3.3 billion ... tab of about 4 percent of annual household income ... University of Oregon,s Climate Leadership Initiative,s Program on Climate ... Economics is guided by a steering committee of 19 ...
... Sessions begin Saturday, March 14 at 10 a.m. SAN FRANCISCO, ... and Wellness Center , is excited to bring back its ... San Francisco. Starting Saturday, March 14 at 10 a.m., ... Park or in the Presidio (near the Lyon Street Stairs) ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 18Health News:LCA-Vision Reports Tangible Results from Business Strategy 2Health News:LCA-Vision Reports Tangible Results from Business Strategy 3Health News:LCA-Vision Reports Tangible Results from Business Strategy 4Health News:LCA-Vision Reports Tangible Results from Business Strategy 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 2Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 3Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 4Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 6Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 7Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 8Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 9Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 10Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 11Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 12Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 13Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 14Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 15
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: